药效团
虚拟筛选
G蛋白偶联受体
腺苷酸环化酶
化学
生物信息学
兴奋剂
配体(生物化学)
效力
部分激动剂
HEK 293细胞
药物发现
反激动剂
立体化学
药理学
受体
计算生物学
生物化学
医学
生物
体外
基因
作者
Hudson R. Smith,Ryan M. Murphy,Michelle A. Hagenimana,John Allen
标识
DOI:10.1124/jpet.294.130118
摘要
Abstract ID 130118 Poster Board 294 GPR52 is an orphan G protein-coupled receptor (GPCR) that is a promising target for neuropsychiatric disorders including schizophrenia and substance abuse disorders. GPR52 is a constitutively active receptor that couples to Gs/olf G proteins to stimulate adenylyl cyclase and increase intracellular cAMP. As with most understudied GPCRs, there is a paucity of structural diversity among known GPR52 ligands. To expand the chemical space of GPR52 ligands, we utilized a proprietary ligand based-pharmacophore model and virtual screening method to identify new potential compounds for GPR52. Greater than 500k synthesis-ready compounds were screened in silico for their structural similarity to the GPR52 agonist c17. This screening provided a compound priority list of 400 predicted GPR52 ligands. These priority compounds were obtained and subsequently screened at 10 μM using a Glosensor cAMP assay in HEK293 cells expressing human GPR52. The primary screen showed 21 hit compounds activated GPR52 cAMP signaling at > 40% of the maximal response to the positive control agonist 4-(3-(3-fluoro-5-(trifluoromethyl) benzyl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-methylbenzamide (FTBMT). Subsequent re-testing confirmed activities, and the five most active compounds were evaluated in concentration responses to determine potency (EC50) and efficacy (Emax). All five compounds exhibited low micromolar potency (ranging from 1.6 to 4.0 μM) and were partial agonists when compared to FTBMT. Two promising validated compounds included 2-B3 (N-(5-{[3-(trifluoromethyl)phenyl]methyl}-1,3-thiazol-2-yl)cyclopropanecarboxamide) and 5-E1 (ethyl 2-benzyl-4-methyl-1,3-thiazole-5-carboxylate). Compound 2-B3 showed lower partial agonist activity (Emax = 39 ± 2%) with a potency (pEC50) of 5.80 ± 0.07 [1.6 μM]. Compound 5-E1 showed moderate partial agonist activity (Emax = 71 ± 2%) and potency (pEC50) of 5.47 ± 0.02 [3.4 μM]. 2-B3 was docked into the previously solved GPR52 crystal structure (PBD 6LI0) using AMDock program. 2-B3 docked into a similar binding site as the agonist c17, with potential hydrogen bonding at the ECL2 amino acid D188. Structural derivatives of agonist 2-B3 are being actively screened to define structure activity relationships important for GPR52 potency and efficacy. Taken together, this virtual screening with pharmacological validation provides a viable method for the discovery of ligands for orphan GPCRs. Compounds 2-B3 and 5-E1 are promising GPR52 agonist ligands amenable to further chemical optimization to expand ligand diversity for GPR52. This work was supported in part by grant# T32DA007287 from the National Institutes of Health and the UTMB Center for Addiction Sciences and Therapeutics.
科研通智能强力驱动
Strongly Powered by AbleSci AI